ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/19 | $85,000,000 | Series A |
Euclidean Capital Kleiner Perkins Caufield and Byers Osage Venture Partners Parker Institute for Cancer Immunotherapy UCSF Foundation Investment Company Westlake Village BioPartners | undisclosed |
| 09/04/24 | $325,000,000 | Series C |
ARCH Venture Partners Bristol-Myers Squibb Hitachi Ventures Kleiner Perkins Caufield and Byers Luma Group Milky Way Investments Group NVentures Parker Institute for Cancer Immunotherapy Regeneron Ventures Rock Springs Capital SoftBank Vision Fund 2 Spring Capital T. Rowe Price Associates Westlake Village BioPartners | undisclosed |
